BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 20.7] [Reference Citation Analysis]
Number Citing Articles
1 Çolaklar A, Altınbaş NK. Infiltrative non-mass-like hepatocellular carcinoma initially presenting with isolated malignant portal vein thrombosis: A case report and review of the literature. J Ultrason 2020;20:e55-60. [PMID: 32320167 DOI: 10.15557/JoU.2020.0009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Fu C, Li J, Li P, Cheng D. LncRNA DNAJC3-AS1 Promotes Hepatocellular Carcinoma (HCC) Progression via Sponging Premature miR-27b. Cancer Manag Res 2021;13:8575-83. [PMID: 34815712 DOI: 10.2147/CMAR.S321111] [Reference Citation Analysis]
3 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
4 Yuan M, Shong K, Li X, Ashraf S, Shi M, Kim W, Nielsen J, Turkez H, Shoaie S, Uhlen M, Zhang C, Mardinoglu A. A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma. Cancers 2022;14:1573. [DOI: 10.3390/cancers14061573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu J, Huang L, Wan M, Chen G, Su M, Han F, Liu F, Xiong G, Liao X, Lu H, Li W, Cao Z. Lenvatinib induces cardiac developmental toxicity in zebrafish embryos through regulation of Notch mediated-oxidative stress generation. Environ Toxicol 2022. [PMID: 35119177 DOI: 10.1002/tox.23485] [Reference Citation Analysis]
6 Gabbia D, Carpi S, Sarcognato S, Cannella L, Colognesi M, Scaffidi M, Polini B, Digiacomo M, Esposito Salsano J, Manera C, Macchia M, Nieri P, Carrara M, Russo FP, Guido M, De Martin S. The Extra Virgin Olive Oil Polyphenol Oleocanthal Exerts Antifibrotic Effects in the Liver. Front Nutr 2021;8:715183. [PMID: 34671630 DOI: 10.3389/fnut.2021.715183] [Reference Citation Analysis]
7 Hassouna MM, Naguib M, Radwan EM, Abdel-Samiee M, Estaphan S, Abdelsameea E. DNA Methyltransferases as Potential Biomarkers for HCV Related Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2020;21:3357-63. [PMID: 33247696 DOI: 10.31557/APJCP.2020.21.11.3357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Huang H, Wang Y, Huang T, Wang L, Liu Y, Wu Q, Yu A, Shi M, Wang X, Li W, Zhang J, Liu Y. FOXA2 inhibits doxorubicin-induced apoptosis via transcriptionally activating HBP rate-limiting enzyme GFPT1 in HCC cells. J Physiol Biochem 2021. [PMID: 34291417 DOI: 10.1007/s13105-021-00829-6] [Reference Citation Analysis]
9 Ancker OV, Krüger M, Wehland M, Infanger M, Grimm D. Multikinase Inhibitor Treatment in Thyroid Cancer. Int J Mol Sci 2019;21:E10. [PMID: 31861373 DOI: 10.3390/ijms21010010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
10 Wu Z, He L, Yang L, Fang X, Peng L. Potential Role of NEU1 in Hepatocellular Carcinoma: A Study Based on Comprehensive Bioinformatical Analysis. Front Mol Biosci 2021;8:651525. [PMID: 34513919 DOI: 10.3389/fmolb.2021.651525] [Reference Citation Analysis]
11 Zou XZ, Hao JF, Zhou XH. Inhibition of SREBP-1 Activation by a Novel Small-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Tissue to Radiofrequency Ablation. Front Oncol 2021;11:796152. [PMID: 34900747 DOI: 10.3389/fonc.2021.796152] [Reference Citation Analysis]
12 Huang R, Chen Z, Li W, Fan C, Liu J. Immune system‑associated genes increase malignant progression and can be used to predict clinical outcome in patients with hepatocellular carcinoma. Int J Oncol 2020;56:1199-211. [PMID: 32319580 DOI: 10.3892/ijo.2020.4998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Li J, Xiong X, Wang Z, Zhao Y, Shi Z, Zhao M, Ren T. In vitro high-throughput drug sensitivity screening with patient-derived primary cells as a guide for clinical practice in hepatocellular carcinoma-A retrospective evaluation. Clin Res Hepatol Gastroenterol 2020;44:699-710. [PMID: 32014387 DOI: 10.1016/j.clinre.2020.01.003] [Reference Citation Analysis]
14 Dash S, Aydin Y, Moroz K. Chaperone-Mediated Autophagy in the Liver: Good or Bad? Cells 2019;8:E1308. [PMID: 31652893 DOI: 10.3390/cells8111308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
15 Feng XY, Chen BC, Li JC, Li JM, Li HM, Chen XQ, Liu D, Li RT. Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice. Phytomedicine 2021;93:153779. [PMID: 34638030 DOI: 10.1016/j.phymed.2021.153779] [Reference Citation Analysis]
16 Keller S, Borde T, Brangsch J, Reimann C, Kader A, Schulze D, Buchholz R, Kaufmann JO, Karst U, Schellenberger E, Hamm B, Makowski MR. Assessment of the hepatic tumor extracellular matrix using elastin-specific molecular magnetic resonance imaging in an experimental rabbit cancer model. Sci Rep 2020;10:20785. [PMID: 33247185 DOI: 10.1038/s41598-020-77624-8] [Reference Citation Analysis]
17 Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers (Basel) 2021;13:2761. [PMID: 34199429 DOI: 10.3390/cancers13112761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Cao S, Zhu S, Yin W, Xu H, Wu J, Wang Q. Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization. Onco Targets Ther 2020;13:9407-17. [PMID: 33061427 DOI: 10.2147/OTT.S257271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Zhang Z, Tan X, Luo J, Yao H, Si Z, Tong JS. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis 2020;11:902. [PMID: 33097691 DOI: 10.1038/s41419-020-03123-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
20 Rezende Miranda R, Fu Y, Chen X, Perino J, Cao P, Carpten J, Chen Y, Zhang C. Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma. J Med Chem 2020;63:11484-97. [PMID: 33030342 DOI: 10.1021/acs.jmedchem.0c00044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Wang L, Li B, Yi X, Xiao X, Zheng Q, Ma L. Circ_0036412 affects the proliferation and cell cycle of hepatocellular carcinoma via hedgehog signaling pathway. J Transl Med 2022;20:154. [PMID: 35382824 DOI: 10.1186/s12967-022-03305-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Patidar Y, Chandel K, Condati NK, Srinivasan SV, Mukund A, Sarin SK. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma – A Retrospective Study. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.12.009] [Reference Citation Analysis]
23 Jiang H, Tang W, Song Y, Jin W, Du Q. Induction of Apoptosis by Metabolites of Rhei Radix et Rhizoma (Da Huang): A Review of the Potential Mechanism in Hepatocellular Carcinoma. Front Pharmacol 2022;13:806175. [PMID: 35308206 DOI: 10.3389/fphar.2022.806175] [Reference Citation Analysis]
24 Ding H, Hu H, Tian F, Liang H. A dual immune signature of CD8+ T cells and MMP9 improves the survival of patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20204219. [PMID: 33656546 DOI: 10.1042/BSR20204219] [Reference Citation Analysis]
25 Huang Z, Zhao B, Qin Z, Li Y, Wang T, Zhou W, Zheng J, Yang S, Shi Y, Fan Y, Xiang R. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis. Eur J Med Chem 2019;181:111541. [PMID: 31382120 DOI: 10.1016/j.ejmech.2019.07.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
26 Duan B, Huang C, Bai J, Zhang YL, Wang X, Yang J, Li J; Department of Medical Oncology, Shaanxi Provincial People’s Hospital, China, Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi’an Jiaotong University, China, Department of Medical Oncology, Shaanxi Provincial People’s Hospital, China, Department of Neurology, Shaanxi Provincial People’s Hospital, China, Department of Medical Oncology, Shaanxi Provincial People’s Hospital, China, Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi’an Jiaotong University, China, Department of National & Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, the Second Affiliated Hospital, Xi’an Jiaotong University, China. Multidrug Resistance in Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 141-58. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 You H, Yuan D, Bi Y, Zhang N, Li Q, Tu T, Wei X, Lian Q, Yu T, Kong D, Yang X, Liu X, Liu X, Kong F, Zheng K, Tang R. Hepatitis B virus X protein promotes vimentin expression via LIM and SH3 domain protein 1 to facilitate epithelial-mesenchymal transition and hepatocarcinogenesis. Cell Commun Signal 2021;19:33. [PMID: 33722250 DOI: 10.1186/s12964-021-00714-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wang Z, Song L, Ye Y, Li W. Long Noncoding RNA DIO3OS Hinders Cell Malignant Behaviors of Hepatocellular Carcinoma Cells Through the microRNA-328/Hhip Axis. Cancer Manag Res 2020;12:3903-14. [PMID: 32547226 DOI: 10.2147/CMAR.S245990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Liu L, Chen A, Chen S, Song W, Yao Q, Wang P, Zhou S. CCNB2, NUSAP1 and TK1 are associated with the prognosis and progression of hepatocellular carcinoma, as revealed by co-expression analysis. Exp Ther Med 2020;19:2679-89. [PMID: 32256749 DOI: 10.3892/etm.2020.8522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Zan Y, Dai Z, Liang L, Deng Y, Dong L. Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment. Drug Deliv 2019;26:1080-91. [PMID: 31735093 DOI: 10.1080/10717544.2019.1654040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
31 Salah RA, Nasr MA, El-Derby AM, Abd Elkodous M, Mohamed RH, El-Ekiaby N, Osama A, Elshenawy SE, Hamad MHM, Magdeldin S, Gabr MM, Abdelaziz AI, El-Badri NS. Hepatocellular carcinoma cell line-microenvironment induced cancer-associated phenotype, genotype and functionality in mesenchymal stem cells. Life Sci 2022;288:120168. [PMID: 34826437 DOI: 10.1016/j.lfs.2021.120168] [Reference Citation Analysis]
32 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Hu W, Zhang L, Dong Y, Tian Z, Chen Y, Dong S. Tumour dormancy in inflammatory microenvironment: A promising therapeutic strategy for cancer-related bone metastasis. Cell Mol Life Sci 2020;77:5149-69. [PMID: 32556373 DOI: 10.1007/s00018-020-03572-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
34 Zhu J, Zhou Y, Wang L, Hao J, Chen R, Liu L, Li J. CXCL5/CXCL8 is a promising potential prognostic and tumor microenvironment-related cluster in hepatocellular carcinoma. J Gastrointest Oncol 2020;11:1364-80. [PMID: 33457007 DOI: 10.21037/jgo-20-556] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Chang YC, Chu TH, Yu PC, Wang EM, Huang CC, Hu TH, Wen ZH, Ko CY, Chen CN, Tai MH. Microalgal extract from thermotolerant Coelastrella sp. F50 retards the liver tumor progression by targeting hepatic cancer stem cells. Phytother Res 2021;35:3954-67. [PMID: 33825221 DOI: 10.1002/ptr.7111] [Reference Citation Analysis]
36 Lim HK, Jeffrey GP, Ramm GA, Soekmadji C. Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles. Front Cell Infect Microbiol 2020;10:587628. [PMID: 33240824 DOI: 10.3389/fcimb.2020.587628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Deng M, Li S, Mei J, Lin W, Zou J, Wei W, Guo R. High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma. Genes (Basel) 2021;12:876. [PMID: 34200261 DOI: 10.3390/genes12060876] [Reference Citation Analysis]
38 Niedźwiedzka-Rystwej P, Grywalska E, Hrynkiewicz R, Wołącewicz M, Becht R, Roliński J. The Double-Edged Sword Role of Viruses in Gastric Cancer.Cancers (Basel). 2020;12. [PMID: 32599870 DOI: 10.3390/cancers12061680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zhu Y, Sun P, Wang K, Xiao S, Cheng Y, Li X, Wang B, Li J, Yu W, Cheng Y. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. Cancer Cell Int 2021;21:503. [PMID: 34537075 DOI: 10.1186/s12935-021-02200-7] [Reference Citation Analysis]
40 Li H, Yang Z, Li R, Lu S, Lu W. Regorafenib Combined With Sirolimus Achieves Successful Treatment of Diffuse Double Lung Metastasis After Liver Transplantation in Giant Liver Cancer Beyond Transplantation Criteria: A Case Report. Transplant Proc 2020;52:634-7. [PMID: 32035675 DOI: 10.1016/j.transproceed.2019.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Yasin HK, Taylor AH, Ayakannu T. A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer. Cancers (Basel) 2021;13:2149. [PMID: 33946913 DOI: 10.3390/cancers13092149] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Liu J, Chen Z, Li W. Machine Learning for Building Immune Genetic Model in Hepatocellular Carcinoma Patients. J Oncol 2021;2021:6676537. [PMID: 33790969 DOI: 10.1155/2021/6676537] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Chisari A, Golán I, Campisano S, Gélabert C, Moustakas A, Sancho P, Caja L. Glucose and Amino Acid Metabolic Dependencies Linked to Stemness and Metastasis in Different Aggressive Cancer Types. Front Pharmacol 2021;12:723798. [PMID: 34588983 DOI: 10.3389/fphar.2021.723798] [Reference Citation Analysis]
44 Deng M, Fang L, Li SH, Zhao RC, Mei J, Zou JW, Wei W, Guo RP. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma. Mutagenesis 2021;36:369-79. [PMID: 34467992 DOI: 10.1093/mutage/geab032] [Reference Citation Analysis]
45 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Rithanya P, Ezhilarasan D. Sodium Valproate, a Histone Deacetylase Inhibitor, Provokes Reactive Oxygen Species-Mediated Cytotoxicity in Human Hepatocellular Carcinoma Cells. J Gastrointest Cancer 2021;52:138-44. [PMID: 32006341 DOI: 10.1007/s12029-020-00370-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
47 Zhu Y, Ke KB, Xia ZK, Li HJ, Su R, Dong C, Zhou FM, Wang L, Chen R, Wu SG, Zhao H, Gu P, Leung KS, Wong MH, Lu G, Zhang JY, Jiang BH, Qiu JG, Shi XN, Lin MC. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma. Mol Med 2021;27:15. [PMID: 33579185 DOI: 10.1186/s10020-021-00269-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
48 Shi T, Iwama H, Fujita K, Kobara H, Nishiyama N, Fujihara S, Goda Y, Yoneyama H, Morishita A, Tani J, Yamada M, Nakahara M, Takuma K, Masaki T. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. Int J Mol Sci 2021;22:13071. [PMID: 34884875 DOI: 10.3390/ijms222313071] [Reference Citation Analysis]
49 Ogawa H, Kaji K, Nishimura N, Takagi H, Ishida K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. J Cell Mol Med 2021;25:4001-13. [PMID: 33609067 DOI: 10.1111/jcmm.16363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Li YT, Wu HL, Liu CJ. Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. Int J Mol Sci 2021;22:9380. [PMID: 34502289 DOI: 10.3390/ijms22179380] [Reference Citation Analysis]
51 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
52 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Mol Med Rep 2020;21:1849-60. [PMID: 32319631 DOI: 10.3892/mmr.2020.10991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
53 Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol 2020;12:1758835920927602. [PMID: 32518599 DOI: 10.1177/1758835920927602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
54 Yu J, Ma S, Tian S, Zhang M, Ding X, Liu Y, Yang F, Hu Y, Xuan G, Zhou X, Wang J, Han Y. Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes. Front Cell Dev Biol 2021;9:700553. [PMID: 34671598 DOI: 10.3389/fcell.2021.700553] [Reference Citation Analysis]
55 Zhao W, Ma B, Tian Z, Han H, Tang J, Dong B, An G, Cao B, Wang B. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance. Br J Cancer 2021;124:1237-48. [PMID: 33473171 DOI: 10.1038/s41416-020-01240-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Nelson Hayes C, Zhang P, Chayama K; Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan. The Role of Lipids in Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 95-110. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
57 Yao Z, Xu R, Yuan L, Xu M, Zhuang H, Li Y, Zhang Y, Lin N. Circ_0001955 facilitates hepatocellular carcinoma (HCC) tumorigenesis by sponging miR-516a-5p to release TRAF6 and MAPK11. Cell Death Dis 2019;10:945. [PMID: 31822654 DOI: 10.1038/s41419-019-2176-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
58 Kannan M, Jayamohan S, Moorthy RK, Chabattula SC, Ganeshan M, Arockiam AJV. AEG-1/miR-221 Axis Cooperatively Regulates the Progression of Hepatocellular Carcinoma by Targeting PTEN/PI3K/AKT Signaling Pathway. Int J Mol Sci 2019;20:E5526. [PMID: 31698701 DOI: 10.3390/ijms20225526] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
59 Borgia M, Dal Bo M, Toffoli G. Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4387. [PMID: 34503196 DOI: 10.3390/cancers13174387] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Meng J, Wei Y, Deng Q, Li L, Li X. Study on the expression of TOP2A in hepatocellular carcinoma and its relationship with patient prognosis. Cancer Cell Int 2022;22:29. [PMID: 35033076 DOI: 10.1186/s12935-021-02439-0] [Reference Citation Analysis]
61 Li J, Liu ZY, Yu HB, Xue Q, Qu XS. Effects of oxymatrine on the proliferation of human liver cancer Bel-7404 cells: A protocol of systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20181. [PMID: 32501970 DOI: 10.1097/MD.0000000000020181] [Reference Citation Analysis]
62 Zhao H, Wang Y, Liu Y, Hao X, Wei H, Xie W. The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism. Anal Cell Pathol (Amst) 2019;2019:5901083. [PMID: 31915594 DOI: 10.1155/2019/5901083] [Reference Citation Analysis]
63 Zhu XL, Li Q, Shen J, Shan L, Zuo ED, Cheng X. Use of 6 m6A-relevant lncRNA genes as prognostic markers of primary liver hepatocellular carcinoma based on TCGA database. Transl Cancer Res 2021;10:5337-51. [PMID: 35116381 DOI: 10.21037/tcr-21-2440] [Reference Citation Analysis]
64 Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Letters 2020;470:8-17. [DOI: 10.1016/j.canlet.2019.12.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 43] [Article Influence: 16.5] [Reference Citation Analysis]
65 Kant R, Yang MH, Tseng CH, Yen CH, Li WY, Tyan YC, Chen M, Tzeng CC, Chen WC, You K, Wang WC, Chen YL, Chen YA. Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structure-Activity Relationship Analysis. J Med Chem 2021;64:8992-9009. [PMID: 34132534 DOI: 10.1021/acs.jmedchem.1c00093] [Reference Citation Analysis]
66 Kim JY, He F, Karin M. From Liver Fat to Cancer: Perils of the Western Diet. Cancers (Basel) 2021;13:1095. [PMID: 33806428 DOI: 10.3390/cancers13051095] [Reference Citation Analysis]
67 Chen T, Du S, Wang S, Wu L, Yin L. Dahuang Zhechong pills inhibit liver cancer growth in a mouse model by reversing Treg/Th1 balance. Chinese Journal of Natural Medicines 2022;20:102-10. [DOI: 10.1016/s1875-5364(22)60160-2] [Reference Citation Analysis]
68 Ying X, Tu J, Wang W, Li X, Xu C, Ji J. FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib. Onco Targets Ther. 2019;12:9303-9307. [PMID: 31807010 DOI: 10.2147/ott.s218796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Hu J, Xing K, Zhang Y, Liu M, Wang Z. Global research Trends in Tyrosine Kinase Inhibitors: A Co-Word and Visualized Study (Preprint). JMIR Medical Informatics. [DOI: 10.2196/34548] [Reference Citation Analysis]
70 Nelson DR, Hrout AA, Alzahmi AS, Chaiboonchoe A, Amin A, Salehi-Ashtiani K. Molecular Mechanisms behind Safranal's Toxicity to HepG2 Cells from Dual Omics. Antioxidants (Basel) 2022;11:1125. [PMID: 35740022 DOI: 10.3390/antiox11061125] [Reference Citation Analysis]
71 Heslop KA, Rovini A, Hunt EG, Fang D, Morris ME, Christie CF, Gooz MB, DeHart DN, Dang Y, Lemasters JJ, Maldonado EN. JNK activation and translocation to mitochondria mediates mitochondrial dysfunction and cell death induced by VDAC opening and sorafenib in hepatocarcinoma cells. Biochem Pharmacol 2020;171:113728. [PMID: 31759978 DOI: 10.1016/j.bcp.2019.113728] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
72 Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
73 Jia M, Guan C, Tao J, Zhou Y, Yan L. Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases. Oxidative Medicine and Cellular Longevity 2022;2022:1-15. [DOI: 10.1155/2022/5042762] [Reference Citation Analysis]
74 Liu Y, Cheng H, Cheng C, Zheng F, Zhao Z, Chen Q, Zeng W, Zhang P, Huang C, Jiang W, Liu X, Liu G. ZNF191 alters DNA methylation and activates the PI3K‐AKT pathway in hepatoma cells via transcriptional regulation of DNMT1. Cancer Medicine. [DOI: 10.1002/cam4.4535] [Reference Citation Analysis]
75 Elkhenany H, Shekshek A, Abdel-Daim M, El-Badri N. Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives. Adv Exp Med Biol 2020;1237:97-119. [PMID: 31728916 DOI: 10.1007/5584_2019_441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
76 Nassar ES, Elkalbashawy YA, Kamal A, Zakaria NHE. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clin Exp Hepatol 2021;7:74-8. [PMID: 34027118 DOI: 10.5114/ceh.2021.104385] [Reference Citation Analysis]
77 Moon H, Ro SW. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3026. [PMID: 34204242 DOI: 10.3390/cancers13123026] [Reference Citation Analysis]
78 Tang G, Zhao H, Xie Z, Wei S, Chen G. Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling. Bioengineered 2022;13:7829-46. [PMID: 35291921 DOI: 10.1080/21655979.2022.2049472] [Reference Citation Analysis]
79 Martínez-chávez A, Tibben MM, Broeders J, Rosing H, Schinkel AH, Beijnen JH. Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium. Journal of Pharmaceutical and Biomedical Analysis 2020;190:113516. [DOI: 10.1016/j.jpba.2020.113516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Demir T, Lee SS, Kaseb AO. Systemic therapy of liver cancer. Adv Cancer Res 2021;149:257-94. [PMID: 33579425 DOI: 10.1016/bs.acr.2020.12.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
81 Liu C, Yu H, Li X, Gong Y, Wu P, Feng QS. Anti-hepatocellular carcinoma efficacy of Fuzheng Xiaozheng prescription and its interventional mechanism studies. J Ethnopharmacol 2022;285:114913. [PMID: 34910953 DOI: 10.1016/j.jep.2021.114913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Liu Y, Chen H, Li X, Zhang F, Kong L, Wang X, Bai J, Wu X. PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma. Front Oncol 2021;11:607021. [PMID: 33718159 DOI: 10.3389/fonc.2021.607021] [Reference Citation Analysis]
83 Nam Y, Shin I, Kim Y, Ryu S, Kim N, Ju E, Sim T. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation. Neoplasia 2022;24:34-49. [PMID: 34864570 DOI: 10.1016/j.neo.2021.11.011] [Reference Citation Analysis]
84 Pang Y, Lin Y, Wang X, Wang J, Liu Q, Ding N, Huang L, Xiang Q, Fang J, Tan G, Lyu J, Wang Z. Inhibition of abnormally activated HIF-1α-GLUT1/3-glycolysis pathway enhances the sensitivity of hepatocellular carcinoma to 5-caffeoylquinic acid and its derivatives. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174844] [Reference Citation Analysis]
85 Liu Y, Zhang J, Chen Y, Sohel H, Ke X, Chen J, Li YX. The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis. Aging (Albany NY) 2020;12:204-23. [PMID: 31905170 DOI: 10.18632/aging.102610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
86 Pan C, Nie W, Wang J, Du J, Pan Z, Gao J, Lu Y, Che J, Zhu H, Dai H, Chen B, He Q, Dong X. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors. Eur J Med Chem 2021;225:113794. [PMID: 34488024 DOI: 10.1016/j.ejmech.2021.113794] [Reference Citation Analysis]
87 Galicia-Moreno M, Silva-Gomez JA, Lucano-Landeros S, Santos A, Monroy-Ramirez HC, Armendariz-Borunda J. Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. Can J Gastroenterol Hepatol 2021;2021:8837811. [PMID: 33728291 DOI: 10.1155/2021/8837811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 Martínez-Chávez A, Broeders J, Lebre MC, Tibben MT, Rosing H, Beijnen JH, Schinkel AH. The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib. Eur J Pharm Sci 2021;159:105740. [PMID: 33524505 DOI: 10.1016/j.ejps.2021.105740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Chen Z, Yu M, Yan J, Zhou B, Zhang W, Guo L, Zhang B, Liu S, Jin L, Zhou J, Fan J, Ye Q, Li H, Xiao Y, Xu Y. Association of intrinsic pathways with altered tumor immune infiltration in hepatocellular carcinoma: New targets for combining immune therapy. Clin Transl Med 2020;10:e219. [PMID: 33252850 DOI: 10.1002/ctm2.219] [Reference Citation Analysis]
90 Ozcan M, Altay O, Lam S, Turkez H, Aksoy Y, Nielsen J, Uhlen M, Boren J, Mardinoglu A. Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach. Adv Biosyst 2020;4:e2000030. [PMID: 32529800 DOI: 10.1002/adbi.202000030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
91 Shang BB, Chen J, Wang ZG, Liu H. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma. PeerJ 2021;9:e12315. [PMID: 34754620 DOI: 10.7717/peerj.12315] [Reference Citation Analysis]
92 Zhuang D, Liang L, Zhang H, Feng X. miR-202 Suppresses Hepatocellular Carcinoma Progression via Downregulating BCL2 Expression. Oncol Res 2020;28:399-408. [PMID: 32272979 DOI: 10.3727/096504020X15864296270581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]